GlobeNewswire·Feb 27, 2026, 8:30 AM ET

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

RenovoRx has tripled the number of U.S. cancer centers requesting access to its FDA-cleared RenovoCath device since Q1 2025, with 33 centers now in the sales pipeline.
Twelve U.S. cancer centers are currently commercially active users of the RenovoCath device, excluding those participating in the ongoing Phase III trial.
Over 700 RenovoCath procedures have been successfully completed since the device received FDA clearance in 2014.
The company appointed Ramtin Agah, MD, Founder, Chairman, and Chief Medical Officer, to the additional position of Executive Chairman to drive commercial growth.
Year-over-year utilization of the TAMP therapy platform is expected to rise, with at least 10 new patients projected to begin treatment in Q1 2026 across the current base of 12 centers.
RenovoRx generated approximately $900,000 in revenue from RenovoCath sales during the first nine months of 2025.
The company's Phase III TIGeR-PaC trial for the IAG drug-device combination candidate (intra-arterial gemcitabine) is nearing completion.
The IAG candidate has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval.
RenovoRx launched its dedicated sales \& marketing team in late 2025 to support increased commercialization efforts \& real-world clinical evidence adoption.